Refine
Has Fulltext
- yes (37)
Is part of the Bibliography
- yes (37)
Year of publication
Document Type
- Journal article (37)
Keywords
- COVID-19 (8)
- acute respiratory distress syndrome (3)
- ECMO-Therapie (2)
- Germany (2)
- airway management (2)
- critical care (2)
- perioperative care (2)
- postoperative nausea and vomiting (2)
- pregnancy (2)
- 6-percent hydroxyethyl starch (1)
- ARDS (1)
- ARDS (acute respiratory distress syndrome) (1)
- Anästhesiologie (1)
- Apple Watch 7 (1)
- Bland–Altman (1)
- COVID 19 (1)
- COVID-19-ARDS (1)
- COVID-19-Pademie (1)
- Central venous-pressure (1)
- ClearSight\(^®\) (1)
- Coronavirus Disease 2019 (1)
- Critically-ill patients (1)
- ECMO therapy (1)
- Elective cesarean-section (1)
- Epidural Analgesia (1)
- Fisher Z-score transformation (1)
- Fitbit Sense (1)
- Garmin Fenix 6 Pro (1)
- Geburtshilfe (1)
- Geburtshilfliche Intensivmedizin (1)
- HCW (1)
- HER2 conversion (1)
- HER2 targeted therapy (1)
- HER2-low (1)
- Healthcare Cost (1)
- Healthcare Economics (1)
- Hypertonic saline 7.5-percent (1)
- ICU staff (1)
- Infektionswellen (1)
- Labour Analgesia (1)
- Labour Pain (1)
- Lactated ringers solution (1)
- Major abdominal surgery (1)
- Patient Controlled Analgesia (1)
- Patient Satisfaction (1)
- Pearson correlation coefficient (1)
- Predict fluid responsiveness (1)
- Puls-pressure variation (1)
- Randomized controlled-trial (1)
- Remifentanil (1)
- SARS-CoV-2 (1)
- Schwangerschaft (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- University Hospital (1)
- Withings ScanWatch (1)
- acute Respiratory Distress Syndrome (1)
- acute kidney injury (1)
- anaesthesiology (1)
- anaesthetics (1)
- analgesics (1)
- anesthesiologists (1)
- anesthetics (1)
- aneurysm repair (1)
- angioplasty (1)
- anticoagulant therapy (1)
- antiemetics (1)
- bioelectronics (1)
- bleeding (1)
- breast cancer (1)
- cardiac protection (1)
- clinical measurement in health technology (1)
- clinical trial (1)
- complications (1)
- conference abstracts (1)
- core outcome set (1)
- coronary artery bypass (1)
- coronavirus disease 2019 (1)
- costs (1)
- critical illness (1)
- cytokines (1)
- data harmonization (1)
- death (1)
- emergency information (1)
- enhanced recovery after surgery (1)
- epidural anaesthesia (1)
- epidural analgesia (1)
- extravascular lung water (1)
- fears (1)
- fish oil (1)
- fitness trackers (1)
- general anesthesia (1)
- graft surgery (1)
- growth differentiation factor 15 (1)
- guideline adherence (1)
- guideline usage (1)
- health care payers (1)
- health care workers (1)
- health sciences (1)
- health tracker (1)
- health-care workers (1)
- human factors (1)
- humans (1)
- immune response (1)
- immunonutrition (1)
- impedance aggregometry; WHOLE-BLOOD THROMBOELASTOMETRY; DEFINITION; DISEASE (1)
- implementation (1)
- inflammation (1)
- infodemic (1)
- information strategies (1)
- intensive care (1)
- intensive care medicine (1)
- internet of things (1)
- intubation (1)
- iron deficiency (1)
- iron deficiency anemia (1)
- laparoscopic surgery (1)
- laryngoscopy (1)
- maternal critical care (1)
- mechanical ventilation (1)
- medicine (1)
- meta-analysis (1)
- minimally invasive surgery (1)
- moderate sedation (1)
- multidisciplinary (1)
- multimodal treatments (1)
- myocardial-infarction (1)
- network meta-analysis (1)
- neurological complications (1)
- nutrient supplementation (1)
- obstetrics (1)
- omega-3 fatty acid (1)
- omega-6 fatty acid (1)
- outcome reporting (1)
- oxidative stress (1)
- pandemia (1)
- parenteral nutrition (1)
- patient safety (1)
- performance (1)
- perioperative setting (1)
- personalized medicine (1)
- photoplethysmography (1)
- point of care testing (1)
- preoperative setting (1)
- primary endpoint (1)
- primary outcome (1)
- pulmonary edema (1)
- quality assurance (1)
- questionnaire (1)
- randomized controlled trial (1)
- robotic surgery (1)
- selective outcome reporting (1)
- selen (1)
- side-effects (1)
- smartwatch (1)
- solnatide (1)
- stent (1)
- supine hypotensive syndrome (1)
- surgery (1)
- survey (1)
- systematic review (1)
- systematic review, (1)
- systemic reviews (1)
- thromboelastometry (1)
- thrombosis (1)
- trastuzumab (1)
- trastuzumab deruxtecan (1)
- trial registration (1)
- vaccination (1)
- vaccination campaign (1)
- vaccination hesitancy (1)
- vaccine (1)
- vaccine hesitancy (1)
- vaccine refusal (1)
- video laryngoscopy (1)
- video-assisted laryngoscopy (1)
- viral load (1)
- volume clamp (1)
- vomiting (1)
- wearable (1)
- zinc (1)
Institute
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (37)
- Frauenklinik und Poliklinik (6)
- Institut für Klinische Epidemiologie und Biometrie (3)
- Kinderklinik und Poliklinik (3)
- Medizinische Klinik und Poliklinik I (3)
- Institut für Informatik (2)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Institut für Experimentelle Biomedizin (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Virologie und Immunbiologie (1)
EU-Project number / Contract (GA) number
- 101003595 (1)
Background: The present anonymous multicenter online survey was conducted to evaluate the application of regional anaesthesia techniques as well as the used local anaesthetics and adjuncts at German and Austrian university hospitals. Methods: 39 university hospitals were requested to fill in an online questionnaire, to determine the kind of regional anaesthesia and preferred drugs in urology, obstetrics and gynaecology. Results: 33 hospitals responded. No regional anaesthesia is conducted in 47% of the minor gynaecological and 44% of the urological operations; plain bupivacaine 0.5% is used in 38% and 47% respectively. In transurethral resections of the prostate and bladder no regional anaesthesia is used in 3% of the responding hospitals, whereas plain bupivacaine 0.5% is used in more than 90%. Regional anaesthesia is only used in selected major gynaecological and urological operations. On the contrary to the smaller operations, the survey revealed a large variety of used drugs and mixtures. Almost 80% prefer plain bupivacaine or ropivacaine 0.5% in spinal anaesthesia in caesarean section. Similarly to the use of drugs in major urological and gynaecological operations a wide range of drugs and adjuncts is used in epidural anaesthesia in caesarean section and spontaneous delivery. Conclusions: Our results indicate a certain agreement in short operations in spinal anaesthesia. By contrast, a large variety concerning the anaesthesiological approach in larger operations as well as in epidural analgesia in obstetrics could be revealed, the causes of which are assumed to be primarily rooted in particular departmental structures.
Background: The German-language recommendations for the management of postoperative nausea and vomiting(PONV) have been revised by an expert committee. Major aspects of this revision are presented here in the form of an evidence-based review article.
Methods: The literature was systematically reviewed with the goal of revising the existing recommendations. New evidence-based recommendations for the management of PONV were developed, approved by consensus, and graded according to the scheme of the Scottish Intercollegiate Guidelines Network (SIGN).
Results: The relevant risk factors for PONV include female sex, nonsmoker status, prior history of PONV, motion sickness, use of opioids during and after surgery, use of inhalational anesthetics and nitrous oxide, and the duration of anesthesia. PONV scoring systems provide a rough assessment of risk that can serve as the basis for a riskadapted approach. Risk-adapted prophylaxis, however, has not been shown to provide any greater benefit than fixed (combination) prophylaxis, and PONV risk scores have inherent limitations; thus, fixed prophylaxis may be advantageous. Whichever of these two approaches to manage PONV is chosen, high-risk patients must be given multimodal prophylaxis, involving both the avoidance of known risk factors and the application of multiple validated and effective antiemetic interventions. PONV should be treated as soon as it arises, to minimize patient discomfort, the risk of medical complications, and the costs involved.
Conclusion: PONV lowers patient satisfaction but is treatable. The effective, evidence-based measures of preventing and treating it should be implemented in routine practice.
Background: Remote ischemic conditioning is gaining interest as potential method to induce resistance against ischemia reperfusion injury in a variety of clinical settings. We performed a systematic review and meta-analysis to investigate whether remote ischemic conditioning reduces mortality, major adverse cardiovascular events, length of stay in hospital and in the intensive care unit and biomarker release in patients who suffer from or are at risk for ischemia reperfusion injury.
Methods and Results: Medline, EMBASE and Cochrane databases were searched for randomized clinical trials comparing remote ischemic conditioning, regardless of timing, with no conditioning. Two investigators independently selected suitable trials, assessed trial quality and extracted data. 23 studies in patients undergoing cardiac surgery (15 studies), percutaneous coronary intervention (four studies) and vascular surgery (four studies), comprising in total 1878 patients, were included in this review. Compared to no conditioning, remote ischemic conditioning did not reduce mortality (odds ratio 1.22 [95% confidence interval 0.48, 3.07]) or major adverse cardiovascular events (0.65 [0.38, 1.14]). However, the incidence of myocardial infarction was reduced with remote ischemic conditioning (0.50 [0.31, 0.82]), as was peak troponin release (standardized mean difference -0.28 [-0.47, -0.09]).
Conclusion: There is no evidence that remote ischemic conditioning reduces mortality associated with ischemic events; nor does it reduce major adverse cardiovascular events. However, remote ischemic conditioning did reduce the incidence of peri-procedural myocardial infarctions, as well as the release of troponin.
Background
The epidural route is still considered the gold standard for labour analgesia, although it is not without serious consequences when incorrect placement goes unrecognized, e.g. in case of intravascular, intrathecal and subdural placements. Until now there has not been a viable alternative to epidural analgesia especially in view of the neonatal outcome and the need for respiratory support when long-acting opioids are used via the parenteral route. Pethidine and meptazinol are far from ideal having been described as providing rather sedation than analgesia, affecting the cardiotocograph (CTG), causing fetal acidosis and having active metabolites with prolonged half-lives especially in the neonate. Despite these obvious shortcomings, intramuscular and intravenously administered pethidine and comparable substances are still frequently used in delivery units.
Since the end of the 90ths remifentanil administered in a patient-controlled mode (PCA) had been reported as a useful alternative for labour analgesia in those women who either don’t want, can’t have or don’t need epidural analgesia.
Discussion
In view of the need for conversion to central neuraxial blocks and the analgesic effect remifentanil has been demonstrated to be superior to pethidine. Despite being less effective in terms of the resulting pain scores, clinical studies suggest that the satisfaction with analgesia may be comparable to that obtained with epidural analgesia. Owing to this fact, remifentanil has gained a place in modern labour analgesia in many institutions.
However, the fact that remifentanil may cause harm should not be forgotten when the use of this potent mu-agonist is considered for the use in labouring women. In the setting of one-to-one midwifery care, appropriate monitoring and providing that enough experience exists with this potent opioid and the treatment of potential complications, remifentanil PCA is a useful option in addition to epidural analgesia and other central neuraxial blocks. Already described serious consequences should remind us not refer to remifentanil PCA as a “poor man’s epidural” and to safely administer remifentanil with an appropriate indication.
Summary
Therefore, the authors conclude that economic considerations and potential cost-savings in conjunction with remifentanil PCA may not be appropriate main endpoints when studying this valuable method for labour analgesia.
Background
There are not enough clinical data from rare critical events to calculate statistics to decide if the management of actual events might be below what could reasonably be expected (i.e. was an outlier).
Objectives
In this project we used simulation to describe the distribution of management times as an approach to decide if the management of a simulated obstetrical crisis scenario could be considered an outlier.
Design
Twelve obstetrical teams managed 4 scenarios that were previously developed. Relevant outcome variables were defined by expert consensus. The distribution of the response times from the teams who performed the respective intervention was graphically displayed and median and quartiles calculated using rank order statistics.
Results
Only 7 of the 12 teams performed chest compressions during the arrest following the 'cannot intubate/cannot ventilate' scenario. All other outcome measures were performed by at least 11 of the 12 teams. Calculation of medians and quartiles with 95% CI was possible for all outcomes. Confidence intervals, given the small sample size, were large.
Conclusion
We demonstrated the use of simulation to calculate quantiles for management times of critical event. This approach could assist in deciding if a given performance could be considered normal and also point to aspects of care that seem to pose particular challenges as evidenced by a large number of teams not performing the expected maneuver. However sufficiently large sample sizes (i.e. from a national data base) will be required to calculate acceptable confidence intervals and to establish actual tolerance limits.
Background:
Studies have reported on the incidence of sedation-related adverse events (AEs), but little is known about their impact on health care costs and resource use.
Methods: Health care providers and payers in five countries were recruited for an online survey by independent administrators to ensure that investigators and respondents were blinded to each other. Surveys were conducted in the local language and began with a "screener" to ensure that respondents had relevant expertise and experience. Responses were analyzed using Excel and R, with the Dixon's Q statistic used to identify and remove outliers. Global and country-specific average treatment patterns were calculated via bootstrapping; costs were mean values. The sum product of costs and intervention probability gave a cost per AE.
Results: Responses were received from 101 providers and 26 payers, the majority having. 5 years of experience. At a minimum, the respondents performed a total of 3,430 procedural sedations per month. All AEs detailed occurred in clinical practice in the last year and were reported to cause procedural delays and cancellations in some patients. Standard procedural sedation costs ranged from (sic)74 (Germany) to $2,300 (US). Respondents estimated that AEs would increase costs by between 16% (Italy) and 179% (US). Hypotension was reported as the most commonly observed AE with an associated global mean cost (interquartile range) of $43 ($27-$68). Other frequent AEs, including mild hypotension, bradycardia, tachycardia, mild oxygen desaturation, hypertension, and brief apnea, were estimated to increase health care spending on procedural sedation by $2.2 billion annually in the US.
Conclusion: All sedation-related AEs can increase health care costs and result in substantial delays or cancellations of subsequent procedures. The prevention of even minor AEs during procedural sedation may be crucial to ensuring its value as a health care service.
Background
Airway management is crucial and, probably, even the most important key competence in anaesthesiology, which directly influences patient safety and outcome. However, high-quality research is rarely published and studies usually have different primary or secondary endpoints which impedes clear unbiased comparisons between studies. The aim of the present study was to gather and analyse primary and secondary endpoints in video laryngoscopy studies being published over the last ten years and to create a core set of uniform or homogeneous outcomes (COS).
Methods
Retrospective analysis. Data were identified by using MEDLINE® database and the terms “video laryngoscopy” and “video laryngoscope” limited to the years 2007 to 2017. A total of 3351 studies were identified by the applied search strategy in PubMed. Papers were screened by two anaesthesiologists independently to identify study endpoints. The DELPHI method was used for consensus finding.
Results
In the 372 studies analysed and included, 49 different outcome categories/columns were reported. The items “time to intubation” (65.86%), “laryngeal view grade” (44.89%), “successful intubation rate” (36.56%), “number of intubation attempts” (23.39%), “complications” (21.24%), and “successful first-pass intubation rate” (19.09%) were reported most frequently. A total of 19 specific parameters is recommended.
Conclusions
In recent video laryngoscopy studies, many different and inhomogeneous parameters were used as outcome descriptors/endpoints. Based on these findings, we recommend that 19 specific parameters (e.g., “time to intubation” (inserting the laryngoscope to first ventilation), “laryngeal view grade” (C&L and POGO), “successful intubation rate”, etc.) should be used in coming research to facilitate future comparisons of video laryngoscopy studies.
Background: Proportions of patients dying from the coronavirus disease-19 (COVID-19) vary between different countries. We report the characteristics; clinical course and outcome of patients requiring intensive care due to COVID-19 induced acute respiratory distress syndrome (ARDS).
Methods: This is a retrospective, observational multicentre study in five German secondary or tertiary care hospitals. All patients consecutively admitted to the intensive care unit (ICU) in any of the participating hospitals between March 12 and May 4, 2020 with a COVID-19 induced ARDS were included.
Results: A total of 106 ICU patients were treated for COVID-19 induced ARDS, whereas severe ARDS was present in the majority of cases. Survival of ICU treatment was 65.0%. Median duration of ICU treatment was 11 days; median duration of mechanical ventilation was 9 days. The majority of ICU treated patients (75.5%) did not receive any antiviral or anti-inflammatory therapies. Venovenous (vv) ECMO was utilized in 16.3%. ICU triage with population-level decision making was not necessary at any time. Univariate analysis associated older age, diabetes mellitus or a higher SOFA score on admission with non-survival during ICU stay.
Conclusions: A high level of care adhering to standard ARDS treatments lead to a good outcome in critically ill COVID-19 patients.